IMVT - Immunovant, Inc.
About Immunovant, Inc. (https://immunovant.com)
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Tiago Girao | Chief Financial Officer | 1979 | $871,065 USD |
| Jay S. Stout | Chief Technology Officer | 1964 | $683,490 USD |
| Melanie Gloria | Chief Operating Officer | 1978 | $575,913 USD |
| Christopher Van Tuyl | Chief Legal Officer & Corporate Secretary | 1976 | $549,038 USD |
| Frank Torti | Executive Chairperson of the Board | 1979 | $92,500 USD |
| Eric Venker | Chief Executive Officer & Director | 1987 | $55,000 USD |
| Andy Deig | Senior Vice President of Strategic Finance | – | – |
| Becky Merlina | Senior VP & Global Head of Quality | – | – |
| Christine Blodgett | Senior Vice President of Human Resources | – | – |
| Julie Kirschling | Senior Vice President of Program & Alliance Management | – | – |
| Sheetal Patel | Senior Vice President of Clinical Development | – | – |
| Yan Zheng | Senior Vice President of Biostatistics, Programming & Data Management | – | – |